➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Moodys
Merck
Dow
Baxter

Last Updated: August 10, 2020

DrugPatentWatch Database Preview

RELENZA Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Relenza, and when can generic versions of Relenza launch?

Relenza is a drug marketed by Glaxosmithkline and is included in one NDA.

The generic ingredient in RELENZA is zanamivir. One supplier is listed for this compound. Additional details are available on the zanamivir profile page.

Drug patent expirations by year for RELENZA
Drug Prices for RELENZA

See drug prices for RELENZA

Recent Clinical Trials for RELENZA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Chinese University of Hong KongPhase 3
Food and Health Bureau, Hong KongPhase 3
Hospital AuthorityPhase 3

See all RELENZA clinical trials

Pharmacology for RELENZA

US Patents and Regulatory Information for RELENZA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline RELENZA zanamivir POWDER;INHALATION 021036-001 Jul 26, 1999 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for RELENZA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline RELENZA zanamivir POWDER;INHALATION 021036-001 Jul 26, 1999   Start Trial   Start Trial
Glaxosmithkline RELENZA zanamivir POWDER;INHALATION 021036-001 Jul 26, 1999   Start Trial   Start Trial
Glaxosmithkline RELENZA zanamivir POWDER;INHALATION 021036-001 Jul 26, 1999   Start Trial   Start Trial
Glaxosmithkline RELENZA zanamivir POWDER;INHALATION 021036-001 Jul 26, 1999   Start Trial   Start Trial
Glaxosmithkline RELENZA zanamivir POWDER;INHALATION 021036-001 Jul 26, 1999   Start Trial   Start Trial
Glaxosmithkline RELENZA zanamivir POWDER;INHALATION 021036-001 Jul 26, 1999   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for RELENZA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0526543 34/1999 Austria   Start Trial PRODUCT NAME: ''ZANAMIVIR'' GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES ODER DERIVATS; NAT. REGISTRATION NO/DATE: 1-23120 19990702; FIRST REGISTRATION: SE 14997 19990209
0526543 SPC/GB99/030 United Kingdom   Start Trial PRODUCT NAME: ZANAMIVIR, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR DERIVATIVE; REGISTERED: SE 14997 19990209; UK PL10949/0327 19990625
0526543 990030 Netherlands   Start Trial PRODUCT NAME: ZANAMIVIRUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT EN/OF VAN EEN FARMACEUTISCH AANVAARDBARE ESTER; NATL. REGISTRATION NO/DATE: RVG 24094 19990707; FIRST REGISTRATION: SE 14997 19990209
0208846 99C0032 Belgium   Start Trial PRODUCT NAME: ZANAMIVIR; NAT. REGISTRATION NO/DATE: NL 24 551 19990726; FIRST REGISTRATION: SE - 14 997 19990209
0526543 C990030 Netherlands   Start Trial PRODUCT NAME: ZANAMIVIRUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT EN/OF VAN EEN FARMACEUTISCH AANVAARDBARE ESTER; NAT. REGISTRATION NO/DATE: RVG 24094 19990707; FIRST REGISTRATION: 14997 19990209
0526543 99C0042 Belgium   Start Trial PRODUCT NAME: ZANAMIVIR; NAT. REGISTRATION NO/DATE: 725 IS 380 F 11 19990906; FIRST REGISTRATION: SE 14997 19990209
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Colorcon
McKesson
AstraZeneca
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.